EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ)

$6.83 -0.42 (-5.7931%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 50

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) News Sources

Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High?

10-08-2026

yahoo.com

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

11-08-2026

yahoo.com

Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients

13-08-2026

yahoo.com

Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences

08-09-2026

yahoo.com

Eupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took Notice

12-09-2026

yahoo.com

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

30-09-2026

yahoo.com

Eupraxia Says Resolve Trial Updated Data Suggest Annual Dosing Possible in EoE Patients

30-09-2026

yahoo.com

Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences

09-10-2026

yahoo.com

Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis

15-10-2026

yahoo.com

Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day

22-10-2026

yahoo.com

EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) Sentiment Trend

0 25 50 75 100 34 84 8 66 59 7 12 74 76 81 10-08-2026 11-08-2026 13-08-2026 08-09-2026 12-09-2026 30-09-2026 09-10-2026 15-10-2026 22-10-2026 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) FAQs

toggle

What is the current price of EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ)?

The current price of EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) is $6.83.


toggle

EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) absolute price change since previous trading day?

The absolute price change of EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) since the previous trading day is $-0.42.


toggle

EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) percentage price change since previous trading day?

The percentage price change of EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) since the previous trading day is -5.7931%.


toggle

What is the most recent average sentiment score for EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ)?

The most recent average sentiment score for EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) is 50 out of 100.


toggle

What is the most recent average sentiment for EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ)?

The most recent sentiment for EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) is .


SEC-8K** Filing Available For EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.